Building bridges to the future of medicine: recommendations for boosting development of novel and companion diagnostics.

Abstract:

:Evaluating the prospects for 'personalized healthcare' has become topical at the 10-year anniversary of the first results from the Human Genome Project. The coincidence of this milestone with a period of global financial difficulty is unfortunate, but industry has signaled its willingness to invest in this new medical paradigm in order to address the problems of high drug candidate attrition as well as escalating healthcare and R&D costs. For diagnostics manufacturers, justifying the ever-growing costs of development without an appropriate framework to provide reasonable return on investment is extremely challenging. Regulators have made good progress in defining what will satisfy current regulatory mandates, but there is still far to go to create conditions that would stimulate investment. My personal perspective is that personalized healthcare represents a solution rather than a problem and herein I describe the bottlenecks slowing development of novel diagnostics from the perspective of a willing commercial stakeholder.

journal_name

Pharmacogenomics

journal_title

Pharmacogenomics

authors

Creeden J

doi

10.2217/pgs.12.143

subject

Has Abstract

pub_date

2012-11-01 00:00:00

pages

1651-9

issue

14

eissn

1462-2416

issn

1744-8042

journal_volume

13

pub_type

杂志文章
  • Vitamin K epoxide reductase complex 1 (VKORC1) haplotypes in healthy Hungarian and Roma population samples.

    abstract::The aim of this work was to determine the VKORC1 haplotype profile in healthy Hungarian and Roma population samples, and to compare our data with other selected populations. Using haplotype tagging SNPs (G-1639A, G9041A and C6009T), we characterized Hungarian (n = 510) and Roma (n = 451) population samples with regard...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.09.46

    authors: Sipeky C,Csongei V,Jaromi L,Safrany E,Polgar N,Lakner L,Szabo M,Takacs I,Melegh B

    更新日期:2009-06-01 00:00:00

  • Integrating pharmacogenomics into drug development.

    abstract::The first observations of inherited differences in drug effects in the 1950s led to the recognition of a genetic basis for drug response. With the development of genetics and molecular biology, it became clear that certain drug responses could be associated with specific genetic variations or polymorphisms. There are ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.3.4.453

    authors: Ferentz AE

    更新日期:2002-07-01 00:00:00

  • Genetic variants associated with warfarin dosage in Kuwaiti population.

    abstract::Assessing the distinct prevalence or absence of genetic variants associated with differential response to the anticoagulant medication of warfarin in different population groups is actively pursued by pharmacogenomics community. Populations from Arabian Peninsula are underrepresented in such studies. By way of examini...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2017-0020

    authors: John SE,Antony D,Eaaswarkhanth M,Hebbar P,Alkayal F,Tuomilehto J,Alsmadi O,Thanaraj TA

    更新日期:2017-06-01 00:00:00

  • Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial.

    abstract:AIM:This study aimed to assess the effectiveness of genotype-guided warfarin dosing. PATIENTS & METHODS:A total of 109 adults were randomized to receive initial dosing as determined by an algorithm containing genetic (VKORC1 and CYP2C9) plus clinical information or only clinical information. Primary end points were th...

    journal_title:Pharmacogenomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2217/pgs.13.145

    authors: Jonas DE,Evans JP,McLeod HL,Brode S,Lange LA,Young ML,Shilliday BB,Bardsley MM,Swinton-Jenkins NJ,Weck KE

    更新日期:2013-10-01 00:00:00

  • Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients.

    abstract:AIM:This study aimed to investigate the effect of CYP3A4 and CYP3A5 genotypes on clinical outcomes of docetaxel treatment. PATIENTS & METHODS:In the PROMIX trial, 150 breast cancer patients received docetaxel preoperatively. CYP3A4 and CYP3A5 genotype combinations were transformed into total CYP 3A phenotypes. RESULT...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2018-0080

    authors: Sim S,Bergh J,Hellström M,Hatschek T,Xie H

    更新日期:2018-11-01 00:00:00

  • Gastric cancer pharmacogenetics: progress or old tripe?

    abstract::Gastric cancer remains the second most frequent cause of cancer-related mortality. While surgery is traditionally the initial treatment for early-stage disease, the addition of chemotherapy has been shown to significantly increase overall survival and progression-free survival in advanced and metastatic stages of dise...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.13.88

    authors: Patel JN,Fuchs CS,Owzar K,Chen Z,McLeod HL

    更新日期:2013-07-01 00:00:00

  • Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array.

    abstract:AIM:We conducted a genome-wide association study using the Illumina Exome Array to identify coding SNPs that may explain additional warfarin dose variability. PATIENTS & METHODS:Analysis was performed after adjustment for clinical variables and genetic factors known to influence warfarin dose among 1680 warfarin users...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2017-0046

    authors: Liu N,Irvin MR,Zhi D,Patki A,Beasley TM,Nickerson DA,Hill CE,Chen J,Kimmel SE,Limdi NA

    更新日期:2017-07-01 00:00:00

  • Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy.

    abstract:INTRODUCTION:Marked lowering of low-density-lipoprotein cholesterol (LDL-C) levels (< or =50%) with intensive statin therapy is associated with major reduction in cardiovascular risk, but is limited by a potential increase in adverse effects, thereby justifying optimization of LDL-C reduction with minimal risk. The org...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2217/14622416.9.9.1217

    authors: Couvert P,Giral P,Dejager S,Gu J,Huby T,Chapman MJ,Bruckert E,Carrié A

    更新日期:2008-09-01 00:00:00

  • Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response.

    abstract:AIM:To investigate the role of genetic polymorphisms in glutamatergic and GABAergic genes and their interactions with environmental stressors in antidepressant response. METHODS:A set of 114 SNPs of 34 glutamatergic and GABAergic genes, mainly in promoter and coding regions, were genotyped in 281 Chinese Han major dep...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.13.1

    authors: Pu M,Zhang Z,Xu Z,Shi Y,Geng L,Yuan Y,Zhang X,Reynolds GP

    更新日期:2013-02-01 00:00:00

  • Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.

    abstract::The potential for personalized sequencing to individually optimize medical treatment in diseases such as cancer and for pharmacogenomic application is just beginning to be realized, and the utility of sequencing healthy individuals for managing health is also being explored. The data produced requires additional advan...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.117

    authors: Esplin ED,Oei L,Snyder MP

    更新日期:2014-11-01 00:00:00

  • Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.

    abstract::Recently, the USA FDA has made a labeling change to the drug information contained in carbamazepine. Owing to recent data implicating the HLA allele B*1502 as a marker for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese, the FDA recommends genotyping all Asians for the alle...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.9.10.1543

    authors: Ferrell PB Jr,McLeod HL

    更新日期:2008-10-01 00:00:00

  • Applicability of gene expression and systems biology to develop pharmacogenetic predictors; antipsychotic-induced extrapyramidal symptoms as an example.

    abstract::Pharmacogenetics has been driven by a candidate gene approach. The disadvantage of this approach is that is limited by our current understanding of the mechanisms by which drugs act. Gene expression could help to elucidate the molecular signatures of antipsychotic treatments searching for dysregulated molecular pathwa...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.15.134

    authors: Mas S,Gassó P,Lafuente A

    更新日期:2015-11-01 00:00:00

  • Conference scene: UK pharmacogenetics and stratified medicine network.

    abstract::The second Annual Meeting of the UK Pharmacogenetics and Stratified Medicine Network was held on 28 September 2011 at The Wellcome Trust Conference Centre on the Wellcome Trust Genome Campus at Hinxton, Cambridge, UK. The meeting preceded the annual Pharmacogenomics and Personalized Medicine conference, which was held...

    journal_title:Pharmacogenomics

    pub_type:

    doi:10.2217/pgs.11.162

    authors: Hall I

    更新日期:2012-01-01 00:00:00

  • Disclosure of individual pharmacogenomic results in research projects: when and what kind of information to return to research participants.

    abstract::In the growing field of genomics, the utility of returning certain research results to participants has become a highly debated issue. Existing guidelines are not explicit as to the kind of genomic information that should be returned to research participants. Moreover, very few current recommendations and articles in ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.13.50

    authors: Korol S,Hurlimann T,Godard B,de Denus S

    更新日期:2013-04-01 00:00:00

  • Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip.

    abstract::Human cytochrome P450 (CYP)3A is a major P450 enzyme found in the liver and gastrointestinal tract. It plays an important role in the metabolism of a wide variety of drugs, some endogenous steroids and harmful environmental contaminants. It has been shown that CYP3A alleles encoding enzymes with little or no activity ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.6.7.731

    authors: Liu CH,Peck K,Huang JD,Lin MS,Wang CH,Hsu WP,Wang HW,Lee HL,Lai ML

    更新日期:2005-10-01 00:00:00

  • Implications of the incidentalome for clinical pharmacogenomics.

    abstract::Incidental findings have long posed challenges for healthcare providers, but the scope and scale of these challenges have increased with the introduction of new technologies. This article assesses the impact of incidental findings on the introduction of prospective pharmacogenomic testing into clinical use. Focusing o...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.13.119

    authors: Brothers KB,Langanke M,Erdmann P

    更新日期:2013-08-01 00:00:00

  • Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study.

    abstract::The successful application of pharmacogenetics in routine clinical practice is still a long way from becoming a reality. In order to favor the transfer of pharmacogenetic results to clinical practice, especially in psychiatry, these studies must be optimized. This article reviews the strengths and weaknesses that char...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,多中心研究,评审

    doi:10.2217/pgs.12.159

    authors: Mas S,Llerena A,Saíz J,Bernardo M,Lafuente A

    更新日期:2012-11-01 00:00:00

  • Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.

    abstract::Mother-to-child-transmission rates of HIV in the absence of any intervention range between 20 and 45%. However, the provision of antiretroviral drugs (ARVs) during pregnancy, delivery and breastfeeding can reduce HIV transmission to less than 2%. Physiological changes during pregnancy can influence ARV disposition. As...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.12.138

    authors: Olagunju A,Owen A,Cressey TR

    更新日期:2012-10-01 00:00:00

  • Genomics, complexity and drug discovery: insights from Boolean network models of cellular regulation.

    abstract::The completion of the first draft of the human genome sequence has revived the old notion that there is no one-to-one mapping between genotype and phenotype. It is now becoming clear that to elucidate the fundamental principles that govern how genomic information translates into organismal complexity, we must overcome...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.2.3.203

    authors: Huang S

    更新日期:2001-08-01 00:00:00

  • Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.

    abstract:AIMS:Survival and response rates in metastatic colorectal cancer remain poor, despite advances in drug development. There is increasing evidence to suggest that gender-specific differences may contribute to poor clinical outcome. We tested the hypothesis that genomic profiling of metastatic colorectal cancer is depende...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.10.163

    authors: Gordon MA,Zhang W,Yang D,Iqbal S,El-Khouiery A,Nagashima F,Lurje G,Labonte M,Wilson P,Sherrod A,Ladner RD,Lenz HJ

    更新日期:2011-01-01 00:00:00

  • IFN-beta pharmacogenomics in multiple sclerosis.

    abstract::Multiple sclerosis (MS) is a condition of the CNS marked by inflammation and neurodegeneration. Interferon (IFN)-beta was the first, and still is the main, immunomodulatory treatment for MS. Its clinical efficacy is limited, and a proportion of patients, ranging between 20-55%, do not respond to the therapy. Identific...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.10.108

    authors: Vandenbroeck K,Urcelay E,Comabella M

    更新日期:2010-08-01 00:00:00

  • Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance.

    abstract:OBJECTIVES:Three exonic single nucleotide polymorphisms (SNPs) in the cytochrome P450 2B6 (CYP2B6) gene, 516G>T, 785A>G and 1459C>T, have been described to be associated with functional changes in the CYP2B6 catalytic activity or protein expression. They are therefore of potential clinical importance for drug efficacy ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.7.7.995

    authors: Rohrbacher M,Kirchhof A,Geisslinger G,Lötsch J

    更新日期:2006-10-01 00:00:00

  • Landscape of warfarin and clopidogrel pharmacogenetic variants in Qatari population from whole exome datasets.

    abstract:AIM:Pharmacogenetic landscapes of commonly used antiplatelet drugs, warfarin and clopidogrel have been studied in-depth in many countries. However, there is a paucity of data to understand their patterns in the Arab populations. MATERIALS & METHODS:We analyzed the whole exome sequencing datasets of 100 Qatar individua...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2016-0130

    authors: Sivadas A,Sharma P,Scaria V

    更新日期:2016-11-01 00:00:00

  • The role of genomics in the discovery of novel targets for antibiotic therapy.

    abstract::The emergence of antibiotic resistance and multi-drug resistance in bacterial pathogens underscores the need for the development of novel classes of antibiotics. The availability of complete genome sequence data from many important human pathogens provides a wealth of fundamental information. This allows us to define ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.3.3.315

    authors: Ji Y

    更新日期:2002-05-01 00:00:00

  • Epigenetics of cancer progression.

    abstract::Alteration in epigenetic regulation of gene expression is a frequent event in human cancer. CpG island hypermethylation and downregulation is observed for many genes involved in a diverse range of functions and pathways that become deregulated in cancer. Paradoxically, global hypomethylation is a hallmark of almost al...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.9.2.215

    authors: Vucic EA,Brown CJ,Lam WL

    更新日期:2008-02-01 00:00:00

  • Genetic factors that confer sensitivity to HAART in HIV-infected subjects: implication of a benefit of an earlier initiation of HAART.

    abstract::EVALUATION OF: Ahuja SK, Kulkarni H, Catano G et al.: CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat. Med. 14(4), 413-420 (2008). It is widely accepted that the effect of highly active antiretroviral therapy (HAART) varies widely among HIV...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.9.9.1347

    authors: Nakajima T,Kimura A

    更新日期:2008-09-01 00:00:00

  • Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications.

    abstract::Second-generation antipsychotics can greatly improve symptoms of psychosis-spectrum disorders. Unfortunately, these drugs are associated with weight gain, which increases a patient's risk for developing chronic diseases including Type 2 diabetes, cardiovascular diseases or other obesity-related complications. There ar...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.11.45

    authors: Lee AK,Bishop JR

    更新日期:2011-07-01 00:00:00

  • Big data in pharmacogenomics: current applications, perspectives and pitfalls.

    abstract::The efficiency of new generation sequencing methods and the reduction of their cost has led pharmacogenomics to gradually supplant pharmacogenetics, leading to new applications in personalized medicine along with new perspectives in drug design or identification of drug response factors. The amount of data generated i...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2018-0184

    authors: Barrot CC,Woillard JB,Picard N

    更新日期:2019-06-01 00:00:00

  • Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients.

    abstract:AIM:The present study explored the integrative effect of genes encoding methadone pharmacokinetic and pharmacodynamic pathways on methadone maintenance doses in Han Chinese Patients. MATERIALS & METHODS:Genomic DNA was extracted from 321 opioid-dependent patients and 202 healthy controls, and realtime-PCR and PCR-RFLP...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.11.96

    authors: Hung CC,Chiou MH,Huang BH,Hsieh YW,Hsieh TJ,Huang CL,Lane HY

    更新日期:2011-11-01 00:00:00

  • Case report: severe toxicity in an African-American patient receiving FOLFOX carrying uncommon allelic variants in DPYD.

    abstract::Cancers of the colon are commonly treated with fluoropyrimidines, which often cause severe toxicities in patients with certain variants in DPYD. Y186C (rs115232898) and a variant in the 3' untranslated region (rs12132152) are uncommon alleles previously observed in African-Americans. An African-American female underwe...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2020-0120

    authors: Sissung TM,Cordes L,Peer CJ,Gandhy S,Redman J,Strauss J,Figg WD

    更新日期:2021-01-01 00:00:00